Filter posts

Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers

After months of criticism, including some from BIO, the Institute for Clinical and Economic Review …

The Washington Post Unfairly Attacks The Orphan Drug Act

The Orphan Drug Act has been a tremendous success and addressed a market failure by …

New Avalere Study: Drugs Not Major Drivers Of Premium Growth, Dispels Insurance Industry Myth

Today, Avalere Health published a study that further dispels the pervasive myth that prescription drugs …

Correcting the Record On Politico’s Misinformed Article

Politico recently explored the relationship between the biopharmaceutical industry and the Affordable Care Act (ACA). …

A Rehash Of Tired, Old Ideas From President Obama

Many of the biopharmaceutical policy proposals laid out by President Obama in his JAMA article …

Bill Gates is Right

In a recent Bloomberg interview, Microsoft founder and noted philanthropist Bill Gates debunked much of …

Bloomberg Caught Spreading Another Inaccurate “False Alarm” About Drug Prices

I was deeply disturbed by Bloomberg’s inaccurate report this morning that attempted to examine drug …

Stop Demeaning the Healthy Dialogue Between Doctors and Drug Companies

A recent report in The Wall Street Journal entitled, “Even Cheap Meals Influence Doctors’ Drug …

Time for AHIP to Finally Join Us And Work Toward A Solution

I worked as an elected leader in government for 24 years. One of the enduring …

ICER's Flawed Methodology Could Lead To Healthcare Rationing

In a column published in USA Today recently, Jeff Stier, a Senior Fellow at the …